NeoStem to Present at 10th Annual Needham Healthcare Conference on Tuesday, April 5

NEW YORK, April 4, 2011 /PRNewswire/ -- NeoStem, Inc. (NYSE Amex: NBS), an international biopharmaceutical company with operations in the U.S. and China, announced today that Dr. Robin L. Smith, Chairman and CEO of NeoStem, will present at the 10th Annual Needham Healthcare Conference on Tuesday, April 5, 2011. The Conference, which runs from April 5-6, 2011, is being held at the New York Palace Hotel at 455 Madison Avenue, New York City, and Dr. Smith will speak from 10:40 to 11:22 AM.

Dr. Smith will review the multiple accomplishments of the Company in 2010 and the outlook in 2011.   Dr Smith will discuss the impact of the Progenitor Cell Therapy, LLC ("PCT") acquisition which is transformative for the company. PCT is an internationally recognized cell therapy services and development company that is involved in the development of therapeutic assets. NeoStem is excited about the prospect of working with PCT to bring these new assets into the clinic this year.

Other accomplishments that will be reviewed will include the development of the Company's China strategy.   In 2010, the Company began generating revenues from what it believes will be the beginning of a pipeline of stem cell-based regenerative medicine therapies, a key element of its growth strategy in China. This has been accomplished with a collaboration with Wendeng and Shijiazhuang Third Hospitals in China whereby patients are offered the benefit of the latest technology from the US in the treatment of a range of orthopedic conditions. These procedures are currently receiving government reimbursement. Additionally, the ongoing relocation of Suzhou Erye Pharmaceutical's new manufacturing facility continues to progress and should be completed in 2011 thereby significantly increasing capacity, unlocking growth.

Dr. Smith will discuss future plans, such as the launch of a new service by bundling together adult stem cell banking and cord blood banking into a multi-generational stem cell collection and storage plan that the Company will call the "Family Plan." Well-recognized television and online healthcare professional, Dr. Manny Alvarez, has been made spokesperson for this new service.

Dr. Smith said, "We believe that adult stem cell collection and banking will become common-place in the decade ahead as multiple new uses for these autologous and vital cells are developed. In a period of concern about nuclear crisis, cell collection makes sense."

According to Needham & Company, LLC, hosts of the Needham Healthcare Conference, more than 100 leading biotechnology, specialty pharma and medical technology companies are scheduled to make presentations to investors.

"Needham's Annual Healthcare Conference assembles some of the most dynamic companies in the biotechnology, specialty pharma and medical technology sectors so that institutional investors and venture capitalists can hear about their latest innovations directly from the source," said Dr. Mark Monane, Managing Director, Equity Research, Biotechnology & Life Sciences, at Needham & Company, LLC. "Attendees have access to public and private companies through one-on-one sessions and moderated company presentations as well as Expert Sessions with academic, clinical and industry professionals."

About NeoStem, Inc.

NeoStem, Inc. is an international biopharmaceutical company with adult stem cell operations in the U.S., a network of adult stem cell therapeutic providers in China as well as a 51% ownership interest in a profitable Chinese generic pharmaceutical manufacturing company.  NeoStem is focused on accelerating the development of proprietary cellular therapies and becoming a single source for collection, storage, manufacturing, therapeutic development and transportation of cells for cell based medicine and regenerative science globally.  The Company also has licensed various cellular therapy technologies, including worldwide exclusive licenses to a wound healing technology and to VSEL™ Technology which uses very small embryonic-like stem cells, which are adult stem cells that have been shown to have several physical characteristics that are generally found in embryonic stem cells.

For more information, please visit: http://www.neostem.com.

About Needham & Company, LLC

Needham & Company, LLC, a wholly owned subsidiary of The Needham Group, Inc., is a privately held, full-service investment bank with the mission of helping emerging growth companies achieve their potential. The firm is headquartered in New York City with offices in Boston, Menlo Park and San Francisco. In addition to investment banking, Needham's principal activities include institutional sales and trading and asset management. To serve its institutional clients, Needham & Company, LLC produces comprehensive equity research on more than 330 companies in clean technology and industrial growth, communications and enterprise infrastructure, consumer, healthcare, semiconductors and semiconductor equipment, and software. Needham & Company, LLC is a member of FINRA, SIPC & SIFMA. For more information, please see www.needhamco.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward looking statements include statements herein with respect to the ability of PCT's business to complement NeoStem's adult stem cell operations and successful execution of the Company's strategy, as well as other advances in the Company's business, about which no assurances can be given. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2010, its Form S-4/A filed with the Securities and Exchange Commission on December 3, 2010 as well as other periodic filings made with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.  NeoStem may experience difficulties in integrating PCT's business and could fail to realize potential benefits of the merger.  Acquisitions may entail numerous risks for NeoStem, including difficulties in assimilating acquired operations, technologies or products, including the loss of key employees from acquired businesses.

SOURCE NeoStem, Inc.